This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Nutrition/ Malnutrition  • Women's Health, Other  • Diagnosis  • Alert me on articles by topic

Suzanne M. Jan de Beur, MD

JAMA. 2005;294:1260-1267.

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic form of renal phosphate wasting that results in severe hypophosphatemia, a defect in vitamin D metabolism, and osteomalacia. This debilitating disorder is illustrated by the clinical presentation of a 55-year-old woman with progressive fatigue, weakness, and muscle and bone pain with fractures. After a protracted clinical course and extensive laboratory evaluation, tumor-induced osteomalacia was identified as the basis of her clinical presentation. In this article, the distinctive clinical characteristics of this syndrome, the advances in diagnosis of TIO, and new insights into the pathophysiology of this disorder are discussed.

Author Affiliation: Department of Medicine, Johns Hopkins University School of Medicine, and Department of Endocrinology, Johns Hopkins Bayview Medical Center, Baltimore, Md.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Rapid Detection of Intact FGF-23 in Tumor Tissue from Patients with Oncogenic Osteomalacia
Mannstadt et al.
Clin. Chem. 2008;54:1252-1254.
FULL TEXT  

Determination of the Elimination Half-Life of Fibroblast Growth Factor-23
Khosravi et al.
J. Clin. Endocrinol. Metab. 2007;92:2374-2377.
ABSTRACT | FULL TEXT  

Update in Osteoporosis and Metabolic Bone Disorders
Shoback
J. Clin. Endocrinol. Metab. 2007;92:747-753.
ABSTRACT | FULL TEXT